There is an increasing availability of geospatial data describing patterns of human settlement and population such as various global remote-sensing based built-up land layers, fine-grained census-based population estimates, and publicly available cadastral and building footprint data. This development constitutes new integrative modelling opportunities to characterize the continuum of urban, peri-urban, and rural settlements and populations. However, little research has been done regarding the agreement between such data products in measuring human presence which is measured by different proxy variables (i.e., presence of built-up structures derived from different remote sensors, census-derived population counts, or cadastral land parcels). In this work, we quantitatively evaluate and cross-compare the ability of such data to model the urban continuum, using a unique, integrated validation database of cadastral and building footprint data, U.S. census data, and three different versions of the Global Human Settlement Layer (GHSL) derived from remotely sensed data. We identify advantages and shortcomings of these data types across different geographic settings in the U.S., which will inform future data users on implications of data accuracy and suitability for a given application, even in data-poor regions of the world.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7531615PMC
http://dx.doi.org/10.1080/17538947.2018.1550120DOI Listing

Publication Analysis

Top Keywords

data
10
urban continuum
8
human settlement
8
cadastral building
8
building footprint
8
footprint data
8
exposing urban
4
continuum implications
4
implications cross-comparison
4
cross-comparison interdisciplinary
4

Similar Publications

Drug Development.

Alzheimers Dement

December 2024

GSK R&D, Stevenage, Hertfordshire, United Kingdom.

Background: Genetic variants in GRN, the gene encoding progranulin, are causal for or are associated with the risk of multiple neurodegenerative diseases. Modulating progranulin has been considered as a therapeutic strategy for neurodegenerative diseases including Frontotemporal Dementia (FTD) and Alzheimer's Disease (AD). Here, we integrated genetics with proteomic data to determine the causal human evidence for the therapeutic benefit of modulating progranulin in AD.

View Article and Find Full Text PDF

Background: Pharmacoepidemiologic studies assessing drug effectiveness for Alzheimer's disease and related dementias (ADRD) are increasingly popular given the critical need for effective therapies for ADRD. To meet the urgent need for robust dementia ascertainment from real-world data, we aimed to develop a novel algorithm for identifying incident and prevalent dementia in claims.

Method: We developed algorithm candidates by different timing/frequency of dementia diagnosis/treatment to identify dementia from inpatient/outpatient/prescription claims for 6,515 and 3,997 participants from Visits 5 (2011-2013; mean age 75.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, North Holland, Netherlands.

The lack of an in-vivo pathology marker for synuclein pathology has been a long standing challenge for dementia for Lewy bodies (DLB) research. This issue is critically important for phase II trials, which are often small, requiring the precise measurement of the biological effects, whether disease modifying or symptomatic. Recent advances have enabled the determination of alpha-synuclein pathology status with CSF measurements, using aggregation assays [RT-QUIC].

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Suven Life Sciences, Hyderabad, Telangana, India.

Background: Alzheimer's disease (AD) agitation is a distressing neuropsychiatric symptom characterized by excessive motor activity, verbal aggression, or physical aggression. Agitation is one of the causes of caregiver distress, increased morbidity and mortality, and early institutionalization in patients with AD. Current medications used for the management of agitation have modest efficacy and have substantial side effects.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Biogen, Cambridge, MA, USA.

Background: Alzheimer's disease (AD) is a progressive neurodegenerative disease characterized by the formation of amyloid-beta (Aβ) plaques and neurofibrillary tangles (NFTs) composed of tau aggregates. Research in animal models has generated hypotheses on the underlying mechanisms of the interaction between Aβ and tau pathology. In support of this interaction, results from clinical trials have shown that treatment with anti-Aβ monoclonal antibodies (mAbs) affects tau pathology.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!